CPI-613 is being evaluated in combination with gemcitabine and nab-paclitaxel for the treatment of locally advanced or metastatic pancreatic cancer, a market characterized by high unmet medical need and limited effective therapies. The combination therapy aims to enhance efficacy and potentially improve patient outcomes compared to standard treatments. Given the aggressive nature of pancreatic cancer and the limited options available, successful outcomes from this trial could position CPI-613 as a significant player in the oncology market, particularly for first-line treatment. The collaboration with Cornerstone Pharmaceuticals indicates a strategic partnership that may enhance development capabilities and market access. However, the competitive landscape includes established therapies and emerging agents, necessitating a robust clinical profile to gain traction.